Tagged: biotech

Syros Pharmaceuticals completed a new $53 million equity offering


syros Syros Pharmaceuticals sold a total of $53.15 million in a non-brokered equity investment round. The transaction which started on October 9th, garnered the support of sixteen investors. Two previous unregistered financing rounds raised an estimated $13.25 million.

Syros Pharmaceuticals develops a proprietary platform that identifies the master switches for disease genes, opening a new approach to novel therapeutics. The company’s initial focus is on cancer, but the platform will also be applicable to other therapeutic areas. Investors include ARCH Venture Partners and Flagship Ventures.

The company, headquartered in Watertown MA, is led by Nancy Simonian (CEO). Syros Pharmaceuticals elected to keep its revenues undisclosed.
The executive team includes Jorge Conde.
The board of directors includes Douglas Cole, James E Bradner, Philip Sharp, Richard A Young, Robert Nelsen, Stephane Bancel and Vicki Sato.

The company has raised an estimated total of $66.4 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Syros Pharmaceuticals
Industry: Biotechnology
Amount offered: $53.15 million
Amount placed: $53.15 million
First sale: 10-09-2014
Data as of: 10-24-2014

For more information visit www.XDATA.co

Advertisements

Eureka Therapeutics reported the completion of a $21 million financing round


XDATA – September 22nd 2014

eurica therapeutics $21 million was raised by Eureka Therapeutics following the successful placement and issuance of its unregistered equity securities. A total of twenty-eight investors participated to the non-brokered placement which started one month ago. No offering was previously initiated by the company under a registration exemption with the SEC.

The company is engaged in the discovery of novel antibody immunotherapies. The company utilizes a paradigm-changing technology platform to develop fully-human antibodies against intracellular cancer antigens.

The company, headquartered in Emeryville CA, is led by Cheng Liu (President). Eureka Therapeutics elected to keep its revenues undisclosed.
The board of directors includes Chih-kai Cheng, Hsing Kung, Qiushi Fu and Sandy Chau.

Offering recap
Status: Completed
Company: Eureka Therapeutics
Industry: Biotechnology
Amount offered: $21 million
Amount placed: $21 million
First sale: 08-20-2014
Data as of: 08-20-2014

For more information visit www.XDATA.co

Emulate files details on its $12 million financing


Emulate raised $12 million from four financial backers on July 11th according to information disclosed by the company. The non-brokered equity offering was fully subscribed. No offering was previously initiated by the company under a registration exemption with the SEC.

Emulate commercializes an automated ‘Organs-on-Chips’ platform that mimics human physiology and diseases, while permitting real-time elucidation of molecular mechanisms of action and toxicity. The company is backed by NanoDimension, Cedars-Sinai Medical Center and private investor Hansjörg Wyss.

The company was registered in 2013 and has its headquarters located in Cambridge MA. Emulate elected to keep its revenues undisclosed.
The executive team includes Daniel Levner, David James Coon, Geraldine A Hamilton and Gregory D Williams.
The board of directors includes Eric Moessinger and Hansjoerg Wyss.

Offering recap
Status: Completed
Company: Emulate
Industry: Biotechnology
Amount offered: $12 million
Amount placed: $12 million
First sale: 07-11-2014
Data as of: 07-28-2014
For more information visit www.XDATA.co

SenGenix revised its offering cap upward to $2.5 million and received $1.97 million in commitments


Change: offered +67% / raised +338% / placed 79%

sengenicsSenGenix upped its financing to $2.5 million from $1.5 million after receiving new commitments. An additional $1.52 million worth of securities was placed by the company with twelve investors since the company last released data almost a year ago. This brings to $1.97 million the amount raised from the fifteen backers who subscribed to the offering. The subscription is structured to close once the 21% left is fully subscribed or in three weeks at the latest. This is the first time securities are issued by SenGenix under a registration exemption.

SenGenix markets and develops point-of-care diagnostic tests (POCT) based on fluorescently responsive sensors (FRS) that will deliver fast, accurate, actionable patient data at a low cost. The product platform is centered around a protein-engineering technology developed at Duke University Medical Center. The company plans on rolling out a stand-alone Creatinine test, and a Basic Metabolic Panel (BMP) consisting of the eight most commonly ordered tests which are Glucose, BUN, Creatinine, Sodium, Potassium, Calcium, Chloride and Bicarbonate.

The company, headquartered in Durham NC, was registered in 2012. SenGenix kept its revenues undisclosed.
The executive team includes Richard S Surwit and Sandra Cummings.
The board of directors includes Homme Hellinga, Lawrence Cohen and Ralph Snyderman.

Offering recap
Status: Intermediary close
Company: SenGenix
Industry: Biotechnology
Amount offered: $2.5 million
Amount placed: $1.97 million
First sale: 08-02-2013
Data as of: 07-07-2014

For more information visit www.XDATA.co

New venture, Inception 5, reports $5 million raised at first close


Inception 5 received two commitments for its $10 million financing round. Investors committed to buy 50% or $5 million worth of equity on June 6th. $5 million in additional funding can be raised before June 2015 based on the placement’s structure. This is the first time Inception 5 is selling securities under a registration exemption.

The company is a biopharmaceutical company dedicated to the research and development of small molecule remyelinating therapies for patients with multiple sclerosis. The company was created and is backed by Roche and Versant Ventures.

Petpiboon Prasit (President and CEO) leads the San Diego CA based company which was registered in 2013. Inception 5 elected to keep its revenues undisclosed.
The executive team includes Thomas Coll.
The board of directors includes Bradley Bolzon.

Offering recap
Status: First close
Company: Inception 5
Industry: Biotechnology
Amount offered: $10 million
Amount placed: $5 million
First sale: 06-06-2014
Data as of: 06-23-2014

For more information visit www.XDATA.co

Reviva Pharmaceuticals reported the completion of a $15.83 million financing round


reviva pharma$15.83 million was raised by Reviva Pharmaceuticals following the successful placement and issuance of its unregistered equity securities. A total of forty-seven investors participated to the non-brokered placement which started almost two weeks ago. Two previous unregistered financing rounds raised an estimated $19.66 million.

Reviva Pharmaceuticals develops new drugs for the central nervous system, metabolic, cardiovascular, inflammation and pain indications. Therapeutic drugs are developed by using an integrated chemical genomics approach and proprietary chemistries.

The company, headquartered in San Jose CA, is led by Laxminarayan Bhat (President and CEO). Reviva Pharmaceuticals elected to keep its revenues undisclosed.

The company has raised an estimated total of $35.5 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Reviva Pharmaceuticals
Industry: Pharmaceuticals
Amount offered: $15.83 million
Amount placed: $15.83 million
First sale: 06-12-2014
Data as of: 06-25-2014

For more information visit www.XDATA.co

$215,000 raised by MetaStat as part of its mezzanine investment round


metastatMetaStat disclosed selling 36% of its non-brokered mezzanine financing. The company launched a $600,000 investment round subscribed so far by six investors. The subscription which raised $215,000 started one month ago. The offering will remain open until May 2015 while an additional $385,000 worth of securities is sold to investors. A total of five unregistered securities offerings closed by the company raised an estimated $15 million.
MetaStat trades under symbol OTC: MTST
The company is a development stage life sciences organization that develops and commercializes diagnostic products and novel therapeutics for the early and prediction and treatment of systemic metastasis – cancer that spreads from a primary tumor through the bloodstream to other areas of the body.
The company is headquartered in Montclair NJ. MetaStat kept its revenues undisclosed.
The executive team includes Daniel Schneiderman, Oscar Bronsther and Warren Lau.
The board of directors includes David Epstein, David Siegel, Johan (thijs) Spoor and Patrick Mooney.The company has raised an estimated total of $15.22 million via private unregistered security offerings.
Offering recap
Status: First close
Company: MetaStat
Industry: Biotechnology
Amount offered: $600,000
Amount placed: $215,000
First sale: 05-22-2014
Data as of: 06-20-2014

For more information visit www.XDATA.co

Lumacyte filed a first close at $30,000


lumacyteLumacyte disclosed selling 2% of its $2 million non-brokered financing round to one investor. According to the filing, $30,000 worth of equity was subscribed a little over a week ago. An additional $1.97 million in funding is to be raised until the offering draws to a close in April 2015. The equity offering’s expected net proceeds will amount to $1.9 million which excludes $100,000 to be paid toward officers’ salaries. This is the first time Lumacyte is selling securities under a registration exemption.

The company developed and produces microfluidic and optics based instruments and sub-components that enable cell biologists, biomedical researchers, pharmaceutical and biotechnology companies to characterize, select, and sort mammalian cell samples without the use of antibody labels.

Sean J Hart (CEO) leads the Keswick VA based company which was registered in 2012. Revenues on or below $1 million were reported by Lumacyte.

The executive team includes Sean Jeffrey Hart.
The board of directors includes Renee Adele Hart.

Offering recap
Status: First close
Company: Lumacyte
Industry: Biotechnology
Amount offered: $2 million
Amount placed: $30,000
First sale: 04-30-2014
Data as of: 05-09-2014

Nu-med Plus disclosed full placement of its $130,000 offering


Change: offered +0% / raised +160% / placed 100%

num med plusNu-med Plus initiated the final close of its $130,000 equity offering. It appears the investor behind the close is the same as disclosed in the company’s latest filing six months ago. The investor’s original commitment stood at $50,000. Up to now Nu-med Plus had raised an estimated $125,000 in unregistered securities via one financing round.

The company develops and commercializes products around its proprietary nitic oxide gas formulation platform.  According to the company, nitric oxide gas has the potential for treating diseases from malaria to the common cold. Inhaled nitric oxide dilates the pulmonary vessels, lowers pulmonary artery pressure, and restores ventilation/perfusion balance in the lungs without significantly affecting the systemic circulation or blood pressure.

The company, headquartered in Salt Lake City UT, is led by Jeffrey L Robins (CEO). No revenues were reported by the company.

The executive team includes Craig W Morrison and William Grant Moon.

In a concurrent filing, Nu-med Plus disclosed having raised $122,000 in a fully subscribed offering.
The company has raised an estimated total of $377,000 via private unregistered security offerings.

Offering recap
Status: Completed
Company: Nu-med Plus
Industry: Biotechnology
Amount offered: $130,000
Amount placed: $130,000
First sale: 10-28-2013
Data as of: 04-30-2014

SQZ Biotech filed a first close at $15,000


SQZ biotechnologiesSQZ Biotech disclosed selling 2% of its $1 million non-brokered financing round to one investor. According to the filing, $15,000 worth of equity was subscribed a little over a week ago. An additional $985,000 in funding is to be raised until the offering draws to a close in March 2015. This is the first time SQZ Biotech Co is selling securities under a registration exemption.

The company commercializes a proprietary process known as “CellSqueeze” built on rapid deformation of cells (“squeezing”) to induce transient disruption of the cell membrane in order to facilitate intracellular delivery of macromolecules without the use of toxic external factors.

The company was registered in 2013 and has its headquarters located in Somerville MA. SQZ Biotech elected to keep its revenues undisclosed.
The executive team includes Agustin Lopez-Marquez, Armon Sharei and Klavs Jensen.
The board of directors includes Robert Langer.

Offering recap
Status: First close
Company: SQZ Biotech
Industry: Biotechnology
Amount offered: $1 million
Amount placed: $15,000
First sale: 03-24-2014
Data as of: 04-03-2014